Cardiovascular disease is a common comorbidity in people living with HIV, and there are several risk factors that can contribute to its development. Chronic immune activation, low CD4 count, high HIV viral load, and exposure to certain classes of antiretroviral (ARV) drugs are all known to increase the risk of cardiovascular disease in this population.

Regular exercise, on the other hand, is actually a protective factor against cardiovascular disease. Exercise has been shown to improve cardiovascular health, reduce inflammation, lower blood pressure, and improve lipid profiles. Therefore, regular exercise is not mentioned as a risk factor for cardiovascular disease in people living with HIV, but rather as a beneficial lifestyle factor that can help reduce the risk of developing cardiovascular complications.

Before a client initiates antiretroviral therapy (ART) for HIV, it is crucial to confirm their HIV status through laboratory testing. This is important because ART is a lifelong commitment and has potential side effects, so it is essential to ensure that the client actually has HIV before starting treatment.

The laboratory evaluation routinely performed to confirm HIV status before initiating ART includes a Confirm HIV test result. This test is typically a more specific and sensitive test than the initial screening test, providing a more accurate diagnosis.

In addition to the Confirm HIV test result, other laboratory evaluations may also be performed before starting ART. These may include a CD4 cell count or percentage, which helps determine the strength of the client’s immune system, as well as tests for creatinine and estimated glomerular filtration rate (eGFR) if tenofovir disoproxil fumarate (TDF) is going to be used in the ART regimen. Haemoglobin levels may also be checked to assess for anemia, which is common in individuals with HIV.

Overall, confirming HIV status through laboratory testing before initiating ART is essential to ensure that the client receives the appropriate treatment and monitoring for their condition.

Human papillomavirus (HPV) is a common sexually transmitted infection that can lead to various health issues, including cervical cancer. Cervical cancer is the most significant long-term risk following an HPV infection because certain types of HPV, such as types 16 and 18, are known to cause changes in the cells of the cervix that can eventually lead to cancer.

Carcinoma of the endometrium, coronary artery disease, endometriosis, and infertility are not directly linked to HPV infection. While HPV can lead to other health issues such as genital warts, the most serious and well-established risk is the development of cervical cancer.

It is important for individuals, especially young women, to get vaccinated against HPV to reduce their risk of developing cervical cancer later in life. Regular screenings, such as Pap smears, can also help detect any abnormal changes in the cervix early on, allowing for prompt treatment and prevention of cervical cancer.

Hepatitis C is a viral infection that affects the liver and can lead to serious health complications if left untreated. In order to conclusively establish the presence of a Hepatitis C infection, various tests can be conducted.

The HCV RNA test is the most sensitive test for detecting Hepatitis C infection, especially in the acute phase. This test looks for the genetic material of the Hepatitis C virus in the blood and can detect the virus as early as 1-2 weeks after infection.

On the other hand, the Anti-HCV test looks for antibodies that the body produces in response to the Hepatitis C virus. However, it can take at least 6 weeks for these antibodies to develop and be detectable in the blood.

Therefore, in the case of a social worker who has been diagnosed with Hepatitis C infection, the HCV RNA test would be the most conclusive test to establish the presence of the infection. This test can provide early and accurate detection of the virus, allowing for prompt treatment and management of the infection.

The guideline for the prevention of vertical transmission of communicable infections, specifically HIV, emphasizes the importance of providing lifelong antiretroviral therapy (ART) to all pregnant women newly diagnosed with HIV. This recommendation is based on the evidence that ART significantly reduces the risk of mother-to-child transmission of HIV, ensuring the health and well-being of both the mother and the baby.

The option Lifelong ART regardless of gestation, CD4 count, or clinical stage is the correct answer because it aligns with the guidelines recommendation. It highlights the importance of initiating ART as soon as possible after diagnosis, regardless of the stage of pregnancy, CD4 count, or clinical symptoms of HIV. This approach ensures that the mother receives the necessary treatment to manage her HIV infection and reduce the risk of transmitting the virus to her baby.

The other options, such as Temporary ART during pregnancy only or ART after delivery if viral load is high, are not in line with the guideline’s emphasis on lifelong ART for pregnant women newly diagnosed with HIV. These options may not provide the optimal protection against mother-to-child transmission of HIV and may compromise the health outcomes for both the mother and the baby.

In conclusion, the guidelines recommendation for lifelong ART for all pregnant women newly diagnosed with HIV reflects the commitment to preventing vertical transmission of HIV and promoting the health and well-being of both the mother and the baby.

The life cycle of Plasmodium species involves both a Dipteran insect host and a vertebrate host. The cycle begins when sporozoites are injected into the vertebrate host’s blood by the insect vector. These sporozoites then infect the host’s liver, where they give rise to merozoites and, in some species, hypnozoites. The merozoites move into the blood and infect red blood cells.

Within the red blood cells, the parasites can either replicate to form more merozoites, which continue to infect more red blood cells, or they can produce gametocytes. Gametocytes are taken up by insects that feed on the vertebrate host. In the insect host, the gametocytes merge to sexually reproduce. After sexual reproduction, the parasites develop into new sporozoites, which then migrate to the insect’s salivary glands.

When the insect bites a vertebrate host, the sporozoites are injected into the host’s blood, continuing the cycle. This complex life cycle ensures the survival and transmission of the Plasmodium species between hosts.

Pregnant women who are newly diagnosed with HIV and initiated on antiretroviral therapy (ART) for the first time need to have their viral load (VL) monitored closely to ensure that the treatment is effective in suppressing the virus. The first VL test is typically conducted at 3 months on ART to assess the response to treatment and to determine if viral suppression has been achieved.

Monitoring the VL at 3 months allows healthcare providers to make any necessary adjustments to the treatment regimen if the viral load is not adequately suppressed. This early assessment is crucial for pregnant women to ensure that the virus is controlled during pregnancy, reducing the risk of mother-to-child transmission of HIV.

By conducting the first VL test at 3 months on ART, healthcare providers can intervene promptly if needed and provide the necessary support to ensure a healthy pregnancy outcome for both the mother and the baby. Regular monitoring of the VL throughout pregnancy is essential to maintain viral suppression and reduce the risk of transmission to the baby.

When considering switching an adolescent from a PI-containing regimen to a DTG-containing regimen, the factor taken into account based on the 2023 ART Clinical Guidelines is the viral load results in the last 12 months. This is because viral load results provide important information about the effectiveness of the current regimen in suppressing the HIV virus. If the viral load has been consistently undetectable or low, it may indicate that the current regimen is working well and there may not be a need to switch to a new regimen. However, if the viral load is high or increasing, it may suggest that the current regimen is not as effective and a switch to a new regimen, such as one containing DTG, may be necessary to better control the virus and prevent further progression of HIV.

Other factors that may also be considered when switching regimens include the adolescent’s weight, the presence of any specific drug allergies, time since the last opportunistic infection, and the adolescent’s preference for tablet size. However, viral load results are a key factor in determining the need for a regimen switch, especially for clients who have been on PI-based regimens for an extended period of time. By monitoring viral load results and making informed decisions based on this information, healthcare providers can ensure that adolescents are receiving the most effective and appropriate treatment for their HIV infection.

Anti-HAV IgM antibodies are diagnostic. Disease in children is more commonly asymptomatic, risk of symptomatic disease increases with age. Transmission is by the faecal-oral route. Faecal shedding has been demonstrated for 2 – 3 weeks before and about a week after, the onset of jaundice. Infection confers lifelong immunity.

Clients diagnosed with DS-TB at a non-neurological site with a CD4 count of less than 50 cells/μL are considered to have advanced HIV disease. In these cases, it is recommended to initiate ART within 2 weeks of starting TB treatment to reduce the risk of mortality and improve outcomes.

Initiating ART early in these patients can help to improve immune function, reduce the risk of opportunistic infections, and decrease the likelihood of TB treatment failure. Delaying ART in these individuals can lead to increased morbidity and mortality due to the high risk of disease progression and complications associated with advanced HIV disease.

Therefore, the correct action to take for clients diagnosed with DS-TB at a non-neurological site with CD4 < 50 cells/μL is to initiate ART within 2 weeks of starting TB treatment. This approach is in line with current guidelines and best practices for the management of HIV/TB co-infection in individuals with advanced HIV disease.